Conflicting data have been reported for Bcl-2, as Charara et al. [27] demonstrated that tumors overexpressing Bcl-2 displayed no residual tumor in response to neoadjuvant chemoradiotherapy, whereas Reerink et al. [28] found no relationship between tumor response in chemoradiotherapy and the level of Bcl-2 expression. This evidence concerns the gene BCL2 and neoplasm.